These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 26435288

  • 21. Lessons in Medical Record Abstraction from the Prostate, Lung, Colorectal, and Ovarian (PLCO) National Screening Trial.
    Bazzi L, Lamerato LE, Varner J, Shambaugh VL, Cordes JE, Ragard LR, Marcus PM.
    Rev Recent Clin Trials; 2015; 10(3):200-5. PubMed ID: 26238207
    [Abstract] [Full Text] [Related]

  • 22. Recruitment methods employed in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Gren L, Broski K, Childs J, Cordes J, Engelhard D, Gahagan B, Gamito E, Gardner V, Geisser M, Higgins D, Jenkins V, Lamerato L, Lappe K, Lowery H, McGuire C, Miedzinski M, Ogden S, Tenorio S, Watt G, Wohlers B, Marcus P.
    Clin Trials; 2009 Feb; 6(1):52-9. PubMed ID: 19254935
    [Abstract] [Full Text] [Related]

  • 23. Screening for cancer: lessons learned from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Grubb RL, Pinsky P, Prorok PC, Andriole GL.
    Eur Urol; 2015 Oct; 68(4):545-6. PubMed ID: 25959167
    [Abstract] [Full Text] [Related]

  • 24. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial.
    Hayes RB, Reding D, Kopp W, Subar AF, Bhat N, Rothman N, Caporaso N, Ziegler RG, Johnson CC, Weissfeld JL, Hoover RN, Hartge P, Palace C, Gohagan JK, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team.
    Control Clin Trials; 2000 Dec; 21(6 Suppl):349S-355S. PubMed ID: 11189687
    [Abstract] [Full Text] [Related]

  • 25. The PLCO Biorepository: Creating, Maintaining, and Administering a Unique Biospecimen Resource.
    Carrick DM, Black A, Gohagan JK, Khan A, Pettit K, Williams C, Yu K, Yurgalevitch S, Huang WY, Zhu C.
    Rev Recent Clin Trials; 2015 Dec; 10(3):212-22. PubMed ID: 26238117
    [Abstract] [Full Text] [Related]

  • 26. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C.
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [Abstract] [Full Text] [Related]

  • 27. Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.
    Prorok PC, Wright P, Riley TR, Kramer BS, Berg CD, Gohagan JK.
    Rev Recent Clin Trials; 2018 Aug; 13(4):257-273. PubMed ID: 29629665
    [Abstract] [Full Text] [Related]

  • 28. The National Cancer Institute Multi-Screening Trial.
    Prorok P.
    Can J Oncol; 1994 Nov; 4 Suppl 1():98-9; discussion 100-1. PubMed ID: 8853500
    [No Abstract] [Full Text] [Related]

  • 29. Minority recruitment in the prostate cancer prevention trial.
    Moinpour CM, Atkinson JO, Thomas SM, Underwood SM, Harvey C, Parzuchowski J, Lovato LC, Ryan AM, Hill MS, Deantoni E, Gritz ER, Thompson IM, Coltman CA.
    Ann Epidemiol; 2000 Nov; 10(8 Suppl):S85-91. PubMed ID: 11189097
    [Abstract] [Full Text] [Related]

  • 30. Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort.
    Lacey JV, Kreimer AR, Buys SS, Marcus PM, Chang SC, Leitzmann MF, Hoover RN, Prorok PC, Berg CD, Hartge P, Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Project Team.
    BMC Cancer; 2009 Mar 17; 9():84. PubMed ID: 19292893
    [Abstract] [Full Text] [Related]

  • 31. ERSPC, PLCO studies and critique of cochrane review 2013.
    Schröder FH.
    Recent Results Cancer Res; 2014 Mar 17; 202():59-63. PubMed ID: 24531778
    [Abstract] [Full Text] [Related]

  • 32. Association of Nonadherence to Cancer Screening Examinations With Mortality From Unrelated Causes: A Secondary Analysis of the PLCO Cancer Screening Trial.
    Pierre-Victor D, Pinsky PF.
    JAMA Intern Med; 2019 Feb 01; 179(2):196-203. PubMed ID: 30592477
    [Abstract] [Full Text] [Related]

  • 33. A randomized trial of recruitment methods for older African American men in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    Ford ME, Havstad SL, Davis SD.
    Clin Trials; 2004 Feb 01; 1(4):343-51. PubMed ID: 16279272
    [Abstract] [Full Text] [Related]

  • 34. Screening for prostate cancer: reflecting on the quality of evidence from the ERSPC and PLCO studies.
    Ilic D.
    Recent Results Cancer Res; 2014 Feb 01; 202():65-71. PubMed ID: 24531779
    [Abstract] [Full Text] [Related]

  • 35. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute.
    Gohagan JK, Prorok PC, Kramer BS, Cornett JE.
    J Urol; 1994 Nov 01; 152(5 Pt 2):1905-9. PubMed ID: 7523735
    [Abstract] [Full Text] [Related]

  • 36. Randomization to screening for prostate, lung, colorectal and ovarian cancers and thyroid cancer incidence in two large cancer screening trials.
    O'Grady TJ, Kitahara CM, DiRienzo AG, Boscoe FP, Gates MA.
    PLoS One; 2014 Nov 01; 9(9):e106880. PubMed ID: 25192282
    [Abstract] [Full Text] [Related]

  • 37. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK, PLCO Project Team.
    J Natl Cancer Inst; 2005 Mar 16; 97(6):433-8. PubMed ID: 15770007
    [Abstract] [Full Text] [Related]

  • 38. The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource.
    Zhu CS, Pinsky PF, Kramer BS, Prorok PC, Purdue MP, Berg CD, Gohagan JK.
    J Natl Cancer Inst; 2013 Nov 20; 105(22):1684-93. PubMed ID: 24115361
    [Abstract] [Full Text] [Related]

  • 39. Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening.
    Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Brawley OW, Wender RC.
    CA Cancer J Clin; 2017 Mar 20; 67(2):100-121. PubMed ID: 28170086
    [Abstract] [Full Text] [Related]

  • 40. Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    Katki HA, Prorok PC, Castle PE, Minasian LM, Pinsky PF.
    J Natl Cancer Inst; 2024 Aug 01; 116(8):1280-1287. PubMed ID: 38603624
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.